Viva Biotech Holdings
Viva Biotech Holdings, a leading player in the biotechnology sector, is headquartered in Shanghai, China, with significant operations across Asia and North America. Founded in 2008, the company has established itself as a pioneer in drug discovery and development, focusing on innovative solutions for the pharmaceutical industry. Viva Biotech offers a range of core services, including structure-based drug design, high-throughput screening, and medicinal chemistry, which are distinguished by their cutting-edge technology and expertise. The company has achieved notable milestones, such as collaborations with major pharmaceutical firms, enhancing its market position as a trusted partner in the drug development process. With a commitment to advancing biopharmaceutical research, Viva Biotech Holdings continues to drive innovation and deliver unique value to its clients.
DitchCarbon Score
How does Viva Biotech Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Viva Biotech Holdings's score of 20 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Viva Biotech Holdings's reported carbon emissions
In 2023, Viva Biotech Holdings reported total carbon emissions of approximately 46.7 million tonnes CO2e, with Scope 1 emissions at about 1.5 million tonnes CO2e and Scope 2 emissions at around 45.3 million tonnes CO2e. This marked a slight decrease from 2022, where emissions were approximately 46.8 million tonnes CO2e. Over the years, the company has shown a trend of increasing emissions, with total emissions rising from about 21.1 million tonnes CO2e in 2019 to 37.5 million tonnes CO2e in 2021, and further to 46.7 million tonnes CO2e in 2023. The breakdown of emissions indicates a significant reliance on indirect emissions (Scope 2), which accounted for the majority of their total emissions in each reporting year. Despite the increasing emissions, there are currently no publicly stated reduction targets or commitments from Viva Biotech Holdings, nor have they engaged with initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). This lack of formal commitments suggests that the company may need to enhance its climate strategy to align with industry standards and expectations for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 22,400 | 000,000 | 000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 2,083,120 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Viva Biotech Holdings is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
